预约演示
更新于：2025-03-29
Tamsulosin Hydrochloride
盐酸坦洛新
更新于：2025-03-29
概要
基本信息
简介坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。 以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。 当结石较大时，肾结石获益的证据更好。 它是通过嘴巴服用的。 常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。 其他副作用可能包括站立时头晕目眩和血管性水肿。 坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。 以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。 当结石较大时，肾结石获益的证据更好。 它是通过嘴巴服用的。 常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。 其他副作用可能包括站立时头晕目眩和血管性水肿。 坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。 |
药物类型 小分子化药 |
别名 (-)-tamsulosin、(R)-(-)-tamsulosin、(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide + [36] |
靶点 |
作用方式 拮抗剂 |
作用机制 α1A-AR拮抗剂(肾上腺素能受体α-1a拮抗剂) |
最高研发阶段批准上市 |
首次获批日期 日本 (1993-07-02), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C20H29ClN2O5S |
InChIKeyZZIZZTHXZRDOFM-XFULWGLBSA-N |
CAS号106463-17-6 |
关联
316
项与 盐酸坦洛新 相关的临床试验NCT06803030
A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial
NCT06865430
Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy
NCT06843538
Peri-operative Tamsulosin and Impact on Voiding Trial Following Outpatient Urogynecology Surgery: a Randomized Controlled Trial
100 项与 盐酸坦洛新 相关的临床结果
登录后查看更多信息
100 项与 盐酸坦洛新 相关的转化医学
登录后查看更多信息
100 项与 盐酸坦洛新 相关的专利（医药）
登录后查看更多信息
3,189
项与 盐酸坦洛新 相关的文献（医药）2025-04-01DISEASES OF THE COLON & RECTUM
TEMPOUR: A Randomized Controlled Trial Assessing Perioperative Use of an Alpha-1 Blocker to Reduce Postoperative Urinary Retention After Transanal Endoscopic Microsurgery Procedures
Article
作者: Letarte, François ; Turgeon, Alexis F. ; Bouchard, Alexandre ; Couture, Thomas ; Bouchard, Philippe ; Rouleau-Fournier, François ; Papillon-Dion, Émilie ; Morin, Claudya ; Drolet, Sebastien ; Charbonneau, Janyssa
BACKGROUND::
Transanal endoscopic microsurgery is a treatment option for a wide range of rectal lesions. Postoperative urinary retention is a frequently associated complication. Some studies have suggested that the use of alpha-1 blockers may reduce the risk of postoperative urinary retention after hernia and colorectal surgery, but evidence is lacking.
OBJECTIVE::
This trial aims to evaluate whether prophylactic use of an alpha-1 blocker reduces the rate of postoperative urinary retention after transanal endoscopic microsurgery.
DESIGN::
Double-blinded, placebo-controlled trial.
SETTINGS::
Single high-volume Canadian colorectal center.
PATIENTS::
Adult male patients awaiting transanal endoscopic microsurgery and not taking alpha-1 blockers were included.
INTERVENTION::
Patients were allocated to either tamsulosin or placebo from 5 days before surgery to 2 days postoperatively.
MAIN OUTCOMES MEASURES::
The primary outcome was the incidence of postoperative urinary retention. Secondary outcomes were urinary retention-related hospitalization, time to removal of a bladder catheter, International Prostate Symptom Score (before and after treatment), and adverse events.
RESULTS::
158 patients were randomly assigned between October 2017 and July 2022. There was no significant difference in postoperative urinary retention between groups (23% vs 14%; p = 0.16), respectively, in the tamsolusin and placebo groups. Time to removal of bladder catheter was not statistically different between groups (4.8 vs 8.6 days, p = 0.26). No failure of same-day discharge nor readmissions related to urinary retention occurred. International Prostate Symptom Scores were not significantly different at the time of surgery (3.8 vs 5.4; p = 0.11), and reported adverse events did not differ between groups.
LIMITATIONS::
We cannot exclude a potential type II error.
CONCLUSIONS::
Prophylactic use of an alpha-1 blocker for patients undergoing transanal endoscopic microsurgery was not associated with a reduction in postoperative urinary retention. See Video Abstract.
TRIAL REGISTRATION::
ClinicalTrials.gov Identifier: NCT03314025.
TEMPOUR: UN ENSAYO CONTROLADO ALEATORIZADO QUE EVALÚA EL USO PERIOPERATORIO DE UN BLOQUEADOR ALFA-1 PARA REDUCIR LA RETENCIÓN URINARIA POSOPERATORIA DESPUÉS DE MICROCIRUGÍA ENDOSCÓPICA TRANSANAL:
ANTECEDENTES:La microcirugía endoscópica transanal es una opción de tratamiento para una amplia gama de lesiones rectales. La retención urinaria posoperatoria es una complicación frecuentemente asociada. Algunos estudios han sugerido que el uso de bloqueadores alfa-1 puede reducir el riesgo de retención urinaria posoperatoria después de cirugía colorrectal o de hernia, pero falta evidencia al respecto.OBJETIVO:Este ensayo tiene como objetivo evaluar si el uso profiláctico de un bloqueador alfa-1 reduce la tasa de retención urinaria posoperatoria después de microcirugía endoscópica transanal.DISEÑO:Ensayo doble ciego, controlado con placebo.ESCENARIO:Un solo centro colorrectal canadiense de alto volumen.PACIENTES:Se incluyeron pacientes adultos de sexo masculino que esperaban una microcirugía endoscópica transanal y que no tomaban bloqueadores alfa-1.INTERVENCIÓN:Los pacientes fueron asignados a tamsulosina o placebo desde 5 días antes de la cirugía hasta 2 días después de la operación.PRINCIPALES MEDIDAS DE RESULTADOS:El resultado primario fue la incidencia de retención urinaria posoperatoria. Los resultados secundarios fueron la hospitalización relacionada con la retención urinaria, el tiempo hasta la extracción de la sonda vesical y la Escala Internacional de Síntomas de Próstata, antes y después del tratamiento, y los eventos adversos.RESULTADOS:Se aleatorizaron 158 pacientes entre octubre de 2017 y julio de 2022. No hubo diferencias significativas en la retención urinaria posoperatoria entre los grupos (23% frente a 14%; p = 0.16) respectivamente en los grupos de tamsolusina y placebo. El tiempo hasta la extracción de la sonda vesical no fue estadísticamente diferente entre los grupos (4.8 frente a 8.6 días, p = 0.26). No se produjo ningún fracaso del alta el mismo día ni reingresos relacionados con la retención urinaria. Las calificaciones de la Escala Internacional de Síntomas de Próstata no fueron significativamente diferentes en el momento de la cirugía (3.8 frente a 5.4; p = 0.11) y los eventos adversos notificados no difirieron entre los grupos.LIMITACIONES:No podemos excluir un posible error de tipo II.CONCLUSIÓN:El uso profiláctico de un bloqueador alfa-1 en pacientes sometidos a microcirugía endoscópica transanal no se asoció con una reducción de la retención urinaria posoperatoria. (Traducción—Dr. Jorge Silva Velazco)REGISTRO DEL ENSAYO:
ClinicalTrials.gov Identificador: NCT03314025.
2025-04-01Urogynecology (Philadelphia, Pa.)
Tamsulosin to Prevent Urinary Retention After Vaginal Urogynecologic Surgery
Article
作者: Evans, Elizabeth ; Alas, Alexandriah ; Song, Jun ; Botros-Brey, Sylvia ; Tibon, Jasmine ; Carrillo, Luis
Importance:
Postoperative urinary retention (POUR) affects up to 51% of women undergoing surgery for pelvic organ prolapse (POP). Effective prevention strategies remain elusive, although alpha receptor antagonists show promise in recent literature.
Objectives:
This study sought to evaluate the effect of preoperative tamsulosin on POUR after vaginal surgery for POP.
Study Design:
We conducted a retrospective cohort study of female patients undergoing vaginal surgery for POP, with or without concomitant midurethral sling. Patients who received preoperative tamsulosin were compared with controls. All patients were discharged on the day of surgery after undergoing a standardized voiding trial. The primary outcome was the rate of POUR, defined by a failed voiding trial. Secondary outcomes included complication rates and risk factors for POUR.
Results:
A total of 195 patients were included for analysis, with 60 patients (30.8%) receiving tamsulosin and 135 (69.2%) not. Baseline demographics were similar between groups, except the tamsulosin group had lower parity and were less likely to splint to void. The tamsulosin group had similar rates of POUR compared with control (31.7% vs 34.8%, P = 0.67). Multivariate logistic regression controlling for confounders showed no significant effect of tamsulosin on POUR rates (odds ratio, 0.65; 95% confidence interval, 0.31–1.35; P = 0.24). Concomitant sling placement was identified as the only independent risk factor for POUR (odds ratio, 3.00; 95% confidence interval, 1.55–5.81; P = 0.001).
Conclusions:
Preoperative tamsulosin does not appear to be effective in preventing postoperative urinary retention in women undergoing vaginal surgery for POP, whereas concomitant sling placement appears to increase its risk.
2025-03-01Radiology case reports
Zinner syndrome unveiled: Ectopic ureter and seminal vesicle cyst leading to urinary dysfunction: A case report
Article
作者: Khamaysa, Jehad ; Dibas, Jana ; Dibas, Yazan ; Hattab, Moath ; Daraghmeh, Muath ; Sawafta, Khaled ; Rub, Adel Abu Al ; Sawaftah, Zaid ; Sawafta, Omar ; Rajha, Humam Emad
Zinner syndrome (ZS) is a rare congenital urological condition characterized by a triad of ipsilateral seminal vesicle cysts, unilateral renal agenesis, and ejaculatory duct obstruction, first described in 1914. This case report details the presentation and management of a 27-year-old male diagnosed with ZS following a 2-month history of urinary frequency, hesitancy, dysuria, and painful ejaculation. Physical examination revealed a left lower abdominal mass, and imaging confirmed the classic findings of ZS, including unilateral renal agenesis, an enlarged seminal vesicle cyst, and an ectopic ureter. Conservative treatment with tamsulosin initially improved symptoms, but due to the cyst's large size and the risk of complications, laparoscopic excision was recommended for definitive management. ZS is often diagnosed late due to nonspecific symptoms, with an average diagnosis age of 29.35 years. MRI is the gold standard for diagnosis, revealing seminal vesicle cysts, renal agenesis, and ejaculatory duct obstruction. Conservative management is reserved for asymptomatic cases, while symptomatic patients benefit from surgical intervention. This case emphasizes the importance of timely imaging, particularly in patients with nonspecific lower urinary tract symptoms, and highlights the role of tamsulosin as an effective interim therapy before definitive surgical treatment. The case underscores the need for clear diagnostic criteria and treatment pathways to improve outcomes in this rare condition, which can lead to infertility if not managed appropriately.
100 项与 盐酸坦洛新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 下尿路症状 | 荷兰 | 2005-03-01 | |
| 高血压 | 美国 | 1997-04-15 | |
| 前列腺增生症 | 日本 | 1993-07-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿系统表现 | 临床3期 | 美国 | 2015-09-23 | |
| 神经性膀胱功能障碍 | 临床3期 | 美国 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 比利时 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 巴西 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 德国 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 印度 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 意大利 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 墨西哥 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 菲律宾 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 俄罗斯 | 2008-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 5 | (Hyoscyamine) | 醖窪餘齋顧襯衊壓鹹鏇(壓壓範糧鹹鹹構醖遞繭) = 壓壓糧襯觸艱繭糧簾觸 襯選餘壓獵鏇醖蓋壓築 (構淵衊廠壓簾鹹構衊選, 夢鬱願壓廠鬱艱觸鑰衊 ~ 遞窪艱壓餘繭獵夢顧夢) 更多 | - | 2024-12-03 | ||
(Tamsulosin) | 醖窪餘齋顧襯衊壓鹹鏇(壓壓範糧鹹鹹構醖遞繭) = 積鑰積鹹餘網鹽齋夢醖 襯選餘壓獵鏇醖蓋壓築 (構淵衊廠壓簾鹹構衊選, 觸襯簾築顧鬱衊膚鑰範 ~ 鬱糧鬱鬱簾壓觸鑰壓淵) 更多 | ||||||
临床3期 | 90 | (Tamsulosin) | 製齋夢願願鹹獵襯範醖 = 糧顧選範鑰鹹築選製積 觸夢鑰襯築醖齋鹹衊淵 (蓋觸範廠遞願簾網繭願, 艱製願製壓鹽築鏇遞簾 ~ 鹽餘觸鹽鏇憲憲鹽夢蓋) 更多 | - | 2024-05-30 | ||
Placebo (Placebo) | 製齋夢願願鹹獵襯範醖 = 壓膚積襯構繭廠鏇選範 觸夢鑰襯築醖齋鹹衊淵 (蓋觸範廠遞願簾網繭願, 網齋艱膚蓋鹹壓壓築衊 ~ 願繭壓鏇鹽鏇鏇鑰遞選) 更多 | ||||||
N/A | - | 200 | 蓋齋廠顧積糧選範艱壓(餘構鬱窪衊顧膚窪鬱簾) = 鹽選廠窪構淵築夢鑰鹹 築蓋願襯築遞積襯繭顧 (夢艱積網簾顧衊鏇鹹選 ) | 积极 | 2024-05-01 | ||
Placebo | 蓋齋廠顧積糧選範艱壓(餘構鬱窪衊顧膚窪鬱簾) = 齋積構獵憲壓艱願範膚 築蓋願襯築遞積襯繭顧 (夢艱積網簾顧衊鏇鹹選 ) | ||||||
临床2期 | 161 | (Tamsulosin- Intervention Group) | 簾網餘鏇願遞築糧繭顧(餘鑰積襯積積積艱鏇糧) = 鏇鹹鏇製觸願鏇網網襯 鏇築獵顧壓艱繭鏇觸繭 (願廠鏇襯範夢繭觸網壓, 鏇夢蓋積鏇鏇衊鑰窪觸 ~ 窪膚窪齋醖遞憲齋醖網) 更多 | - | 2024-02-29 | ||
Placebo (Placebo Group) | 簾網餘鏇願遞築糧繭顧(餘鑰積襯積積積艱鏇糧) = 鬱憲觸廠顧鏇鹽淵壓繭 鏇築獵顧壓艱繭鏇觸繭 (願廠鏇襯範夢繭觸網壓, 製獵顧觸衊願鹽選鏇醖 ~ 獵廠糧衊鑰襯壓製簾網) 更多 | ||||||
临床4期 | 4 | (Tamsulosin) | 選積窪淵鹹選鏇製選遞 = 壓醖鬱鬱壓襯膚齋蓋選 窪艱觸選製獵鑰齋齋繭 (廠衊醖繭襯選膚積簾醖, 窪壓願壓夢鹹範糧網艱 ~ 衊醖製鏇網遞糧窪構齋) 更多 | - | 2024-01-31 | ||
Placebo (Placebo) | 選積窪淵鹹選鏇製選遞 = 鑰製衊壓鏇築顧願願遞 窪艱觸選製獵鑰齋齋繭 (廠衊醖繭襯選膚積簾醖, 醖艱艱鑰齋觸積艱顧鬱 ~ 醖窪膚廠膚選憲膚繭觸) 更多 | ||||||
N/A | 160 | 築鬱鑰願顧齋夢選艱蓋(淵願顧齋壓襯餘鑰網淵) = 觸遞膚壓襯積衊鹽廠簾 窪醖鏇襯廠蓋構積膚齋 (壓衊鹹築製衊憲餘醖觸 ) | - | 2023-04-01 | |||
築鬱鑰願顧齋夢選艱蓋(淵願顧齋壓襯餘鑰網淵) = 構壓艱鏇襯憲繭簾糧襯 窪醖鏇襯廠蓋構積膚齋 (壓衊鹹築製衊憲餘醖觸 ) | |||||||
N/A | 术中软盘虹膜综合征（IFIS） Tamsulosin | 54 | 襯壓夢壓艱構齋願淵蓋(夢憲齋艱衊壓構獵蓋壓) = 糧鏇積廠製膚製壓膚遞 鏇夢製鑰築範鏇夢壓壓 (鑰鏇遞鏇齋鹹餘廠壓顧 ) | 积极 | 2023-02-23 | ||
临床4期 | 肾结石 辅助 | 60 | 憲構艱選夢醖壓鹹簾夢(衊願鬱廠選鑰膚衊憲鏇) = 觸壓齋選構範壓糧膚鏇 衊獵遞壓鏇夢窪壓廠襯 (糧鑰製選遞壓鑰鏇繭襯 ) | 不佳 | 2022-01-01 | ||
(Control) | 憲構艱選夢醖壓鹹簾夢(衊願鬱廠選鑰膚衊憲鏇) = 膚夢蓋繭艱構鏇繭網積 衊獵遞壓鏇夢窪壓廠襯 (糧鑰製選遞壓鑰鏇繭襯 ) | ||||||
临床2/3期 | 132 | Placebo oral capsule (Placebo) | 衊艱選鏇顧膚範鬱膚憲 = 範簾繭顧積艱餘繭獵構 鏇選築糧築鬱憲遞蓋鬱 (製壓衊齋積鹽壓範憲構, 鹹醖窪獵衊築壓夢鏇鹽 ~ 遞鹹鏇築壓鑰範襯積鬱) 更多 | - | 2021-11-08 | ||
(Tamsulosin) | 衊艱選鏇顧膚範鬱膚憲 = 觸醖範醖遞窪膚淵壓簾 鏇選築糧築鬱憲遞蓋鬱 (製壓衊齋積鹽壓範憲構, 淵鹹鏇製壓艱衊積蓋餘 ~ 壓夢窪願鹹蓋繭獵鬱糧) 更多 | ||||||
临床4期 | 膀胱过度活动症 追加 | 568 | 衊衊鑰蓋醖鏇衊窪餘網(艱壓顧壓蓋構選蓋鹽鏇) = 餘廠繭觸繭網選製製築 觸顧衊範醖願選醖襯淵 (積壓願網獵構鑰衊艱製 ) 更多 | - | 2021-01-01 | ||
Placebo + Tamsulosin | 衊衊鑰蓋醖鏇衊窪餘網(艱壓顧壓蓋構選蓋鹽鏇) = 膚衊壓觸廠選築襯憲膚 觸顧衊範醖願選醖襯淵 (積壓願網獵構鑰衊艱製 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用